# A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Tollerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.

> **NCT01160003** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GW870086X
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01160003
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-29
- **Primary completion:** 2010-11-05
- **Final completion:** 2010-11-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160003, "A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Tollerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01160003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*